RiHeart，一种基于iPS细胞的片材，在2025年大阪世博会展出后已投入心脏手术的实际应用。| Cuorips / via JIJI Jiji Oct 20, 2026 2025年大阪世博会展出的技术，包括一种由诱导多能干细胞（iPS）制成的心肌细胞片，正逐步得到实际应用。
RiHeart, an iPS cell-based sheet, has been put into practical use for heart surgery after it was exhibited at the 2025 Osaka Expo. | Cuorips / via JIJI Jiji Oct 20, 2026 Technologies showcased at the 2025 World Exposition in Osaka, including a sheet of heart muscle cells made from induced pluripotent stem (iPS) cells, are seeing growing practical applications.
“这将解决无望的情况，”大阪大学衍生的初创公司Cuorips的执行副总裁平良和义表示，谈到该公司的iPS细胞片RiHeart。
“This would resolve a hopeless situation,” Kazuyoshi Hirao, executive vice president of Cuorips, a startup originating from the University of Osaka, said of the company’s iPS cell-based sheet, RiHeart.
缺血性心肌病患者因血管堵塞导致心肌功能失调，病情严重时需要接受心脏移植。在许多情况下，他们需要等待超过五年才能接受移植。
Patients with ischemic cardiomyopathy, in which clogged blood vessels prevent the heart muscle from functioning properly, need to receive a heart transplant when the condition becomes serious. In many cases, they need to wait for over five years before receiving a transplant.